Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply
Fierce competition and threat of Trump tariffs lead to Danish company cutting costsSales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs a…